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Abstract: Proteasome inhibition forms the cornerstone of antimyeloma therapy. The 
  first-in-class proteasome inhibitor, bortezomib, either alone or in combination with other 
chemotherapeutic agents, induces high overall response rates and response qualities in patients 
with clinically and molecularly defined high-risk disease. However, resistance to bortezomib 
and neurotoxicity associated with the treatment remain challenging issues. Carfilzomib is a 
novel, well tolerated, irreversible proteasome inhibitor with minimal neurotoxicity. Carfilzomib 
demonstrates promising activity in myeloma patients who are refractory to bortezomib and 
immunomodulatory agents. This review focuses on the pharmacology, safety, and efficacy 
of carfilzomib for the treatment of multiple myeloma in bortezomib-naïve and bortezomib-
exposed populations.
Keywords: carfilzomib, multiple myeloma, pharmacology, safety, efficacy
Core evidence clinical impact summary for carfilzomib in multiple myeloma (MM)
Outcome measure Evidence Implications
Disease-oriented evidence
Response rate Substantial Patients with refractory MM 
have partial and complete 
response to drug
improvement in quality of life Substantial Patients had minimal to no 
development of peripheral 
neuropathy
Patient-oriented evidence
Safety and tolerability Moderate Grade 3 and 4 toxicities were 
observed but infrequently led 
to dose limitations
Dyspnea Absolute 6% increase in 
the incidence of dyspnea in 
patients treated with ticagrelor
it may affect long-term 
compliance if the agent is  
to be used routinely
Economic evidence Unknown The drug has not yet been 
approved by US FDA for use 
in relapsed/refractory MM
Introduction
Overall survival in multiple myeloma has improved significantly in the last decade. 
The emergence of new classes of drugs used as single agents or in combination 
has changed the natural history of the disease. Immunomodulatory drugs, such as 
thalidomide and lenalidomide, and proteasome inhibitors, such as bortezomib, when Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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administered with conventional chemotherapeutic agents,1–7 
have begun to rival the benefits seen with autologous stem 
cell transplantation. However, the majority of patients (even 
those who respond) eventually develop resistance over time 
by mechanisms that remain obscure. Early reports indicate 
that increased and/or altered proteasome subunit expression 
may play a role in acquired drug resistance to bortezomib, 
a reversible proteasome inhibitor approved for the treatment 
of multiple myeloma in both frontline and relapsed or refrac-
tory settings.8,9 This appears to be especially the case for the 
β5-proteasome subunit, which exhibits chymotrypsin-like 
activity and is the major target for bortezomib. Its overexpres-
sion and mutation have induced bortezomib resistance in sev-
eral in vitro models.9–12 In addition to the acquired resistance, 
painful peripheral neuropathy is a common dose-limiting 
toxicity of bortezomib, limiting its use in many patients. Most 
recently, a subcutaneous dosing schedule of bortezomib has 
been developed which appears to be associated with a sub-
stantially lower maximum concentration of exposure, with 
a roughly equivalent area under the curve of exposure and 
efficacy in patients with multiple myeloma.13 Interestingly, 
this alternative route of administration is also associated with 
a marked reduction in neuropathy, leading many to believe 
that the high maximum concentration exposure of bortezomib 
may be the primary basis for the neuropathy. It is also unclear 
whether this toxicity can be attributed to a host of alternative 
off-target effects, given the pleiotropic properties   associated 
with proteasome inhibition. Collectively, these findings 
  suggest the need for alternative proteasome inhibitors with 
an improved safety profile that may affect the proteasome in 
an irreversible fashion. Carfilzomib (formerly PR-171) is a 
novel proteasome inhibitor of the epoxyketone class that is 
structurally and mechanistically distinct from bortezomib.14 
It is an irreversible inhibitor of the proteasome that seems to 
be more selective for chymotrypsin-like protease, with less 
affinity for the trypsin and caspase-like proteases in the 26S 
proteasome. Preclinical and early-phase clinical studies of 
carfilzomib in patients with hematologic malignancies and 
multiple myeloma show promise.
Chemical structure and biochemical 
pharmacology
The ubiquitin-proteasome system pathway is the major 
nonlysosomal process responsible for maintaining cel-
lular protein homeostasis via timely degradation of most 
intracellular proteins. Consequently, its inhibition affects 
numerous signaling pathways that regulate fundamental 
cellular functions, such as signal transduction, cell cycle 
progression (eg, cyclins), apoptosis (eg, Noxa, Bcl2/Bax), 
and the stress response (for example, misfolded and par-
tially assembled proteins). Importantly, cancer cells appear 
to be particularly dependent on these proteasome-regulated 
homeostatic pathways.15–18 For a protein to be recognized 
by the proteasome, ubiquitin, a 76-residue polypeptide, 
must first be conjugated to the target protein. This pro-
cess is carried out by a cascade of enzymes, including the 
  ubiquitin-activating enzyme, the ubiquitin-conjugating 
enzyme, and ubiquitin ligase, which ultimately ubiquti-
nylates the target protein. Ubiquitin ligase binds to the 
target protein and interacts with the ubiquitin-conjugating 
enzyme to attach covalently a polyubiquitin chain of 
at least four units that flags the protein for destruction 
by the   proteasome. This ubiquitin tagging earmarks the 
target protein for the 19S regulatory cap, where, in an 
  ATP-dependent fashion, the protein is converted to its pri-
mary structure. Once denatured, the protein is internalized 
into the core of the 26S proteasome, where it undergoes 
proteolytic degradation via the proteases contained in the 
β-ring of the proteasome. The 26S proteasome is comprised 
of a 20S core containing three active enzymatic sites, 
including the chymotrypsin-like (β5), trypsin-like (β2), 
and post-glutamyl peptide hydrolase-like (caspase-like, 
β1) activities, plus a 19S regulatory cap at either end.19 
Of these proteases, the chymotrypsin-like activity of the 
proteasome is most sensitive to inactivation.20,21
The immunoproteasome (20Si) is a specialized type of 
proteasome that is mainly found in monocytes and lympho-
cytes, and is known to be important for generating certain 
peptide antigens for major histocompatibility complex class I 
presentation. Upon stimulation with interferon-gamma or 
tumor necrosis factor-alpha, a change occurs in the protease 
subunit composition, leading to the replacement of β5, 
Drug name Carfilzomib
Developmental stage Non-randomized phase II treatment of Multiple Myeloma
Mechanism of action Selective, irreversible 20S proteasome inhibition
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β2, and β1 by low molecular mass polypeptide 7 (LMP7), 
also known as β5i, multicatalytic endopeptidase complex 
subunit (MECL1), also known as β2i, and LMP2, also 
known as β1i. Preferential expression of 20Si has also been 
observed in multiple myeloma, suggesting that specific 
immunoproteasome inhibition could be a promising thera-
peutic strategy as well.22 Bortezomib and carfilzomib both 
appear to target the constitutive proteasome and immuno-
proteasome indiscriminately.
Carfilzomib is a structural analog (Figure 1) of the 
microbial natural product, epoxomicin 3, that was initially 
identified for its antitumor activity and subsequently shown 
to be a potent inhibitor of the proteasome.14,21 Carfilzomib 
selectively inhibits the chymotrypsin-like activity of the 20S 
proteasome and displays equivalent potency against β5 and 
LMP7, and has minimal cross-reactivity with other protease 
classes (Figure 2). Proteasome inhibition by carfilzomib is 
mechanistically irreversible,14,22–24 and requires new protein 
synthesis for recovery of cellular proteasome activity. Con-
sequently, the proteasome inhibition by carfilzomib is more 
sustained compared with that of the slowly reversible inhibitor, 
bortezomib.14 The epoxybutane pharmacophore of carfilzomib 
exhibits a high level of specificity for the NH2-terminal threo-
nine residue that catalyzes enzymatic activity in each of the 
proteolytic active sites within the proteasome.23 Carfilzomib 
shows minimal activity against off-target enzymes, including 
serine proteases.25 In contrast, the boronate pharmacophore 
of bortezomib reacts with active-site serine residues found in 
β1
β2
β5
β2
β4 β4
β3
β7
β6 β5
β7
Constitutive proteasome Immunoproteasome
Caspase like
activity
Trypsin like
activity
MECL1
LMP7
LMP2
Chymotrypsin
 like activity
CFZ CFZ
Figure 2 Cross sectional view of the carfilzomib binding site in the 20S proteasome and immunoproteasome.
Table 1 Key biochemical and pharmacologic differences between major proteasome inhibitors in clinical use
Properties Bortezomib Carfilzomib NPI-0052
Active moiety Dipeptide boronic acid analog Peptide epoxyketone Nonpeptide bicyclic ®-lactam  
β-lactone
20S proteasome  
(20Si)
β5 mainly 
LMP7 and β1
β5 mainly 
LMP7
β5 and β2 
Not reported
iC50S (nM)
Chymotrypsin 2.4–7.9 6 3.5
Trypsin 590–4200 3600 28
Caspase 24–74 2400 430
iC50 values across MM cell line RPMi-8226 (nM) 5.7 5 9.1
Binding kinetics Slowly reversible irreversible irreversible
Half-life 110 minutes ,30 minutes ,10–15 minutes
Maximal percent of proteasome inhibition at 
maximum tolerated dose
65%–75% .80% 100%
Abbreviations: LMP7, low molecular mass polypeptide 7; MM, multiple myeloma; β1, β1-proteasome subunit; β2, β2-proteasome subunit; β5, β5-proteasome subunit.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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serine proteases including chymotrypsin, cathepsins A and G, 
elastase, and chymase,26,27 albeit at concentrations higher than 
required to inhibit the proteasome. Parlati et al confirmed the 
above observations, and recently demonstrated that 20Si is 
a major form of the proteasome expressed in hematopoietic 
cells, including multiple myeloma CD138+ tumor cells.28 
Although specific inhibition of either LMP7 or β5 alone was 
insufficient to produce an antitumor response, inhibition of 
all proteasome subunits was cytotoxic to both hematopoietic 
tumor cells and peripheral blood mononuclear cells. However, 
selective inhibition of both β5 and LMP7 was sufficient for 
the antitumor effect in multiple myeloma, non-Hodgkin’s 
lymphoma, and leukemia cells, while exhibiting minimal 
toxicity towards nontransformed cells. In multiple myeloma, 
chymotrypsin-like inhibition alone was sufficient to induce 
apoptosis. Differences between the major proteasome inhibi-
tors with respect to the biochemical and pharmacological 
properties are listed in Table 1.
Preclinical activity
in vitro activity in multiple myeloma
Carfilzomib has been shown to induce apoptosis, cell cycle 
arrest, and activation of stress response pathways in a vari-
ety of human tumor cell lines, including multiple myeloma, 
Burkitt’s lymphoma, acute lymphoblastic leukemia, B cell 
non-Hodgkin’s lymphoma, colorectal adenocarcinoma, 
pancreatic cancer, and lung cancer.14 Demo et al have dem-
onstrated that carfilzomib is more cytotoxic than bortezomib 
in cell culture following brief treatment, and that hematologic 
tumor cells exhibit the greatest sensitivity to brief exposure, 
whereas solid tumor cells and nontransformed cells were 
less sensitive to such treatments. There was no difference 
in the onset of proteasome inhibition between carfilzomib 
and bortezomib, eliminating the possibility that cell perme-
ability could be a possible explanation for the difference 
in cytotoxicity. Extended exposure to carfilzomib (from 
1–6 hours) typically produces greater cytotoxicity due to a 
time-dependent increase in proteasome inhibition and sup-
pression of proteasome recovery.
Kuhn et al confirmed the potent and specific inhibition of 
the chymotrypsin subunit of the proteasome by carfilzomib, 
resulting in accumulation of the ubiquitinated substrates. 
They also demonstrated inhibition of the immunoproteasome 
by carfilzomib.29 Carfilzomib inhibited the proliferation of 
both interleukin-6-dependent ANBL-6 and KAS-6 multiple 
myeloma cell lines, as well as interleukin-6-independent 
lines, such as RPMI 8226 and U266, in a concentration-
dependent and time-dependent manner. Greater antiprolifera-
tive effects were seen across previously untreated multiple 
myeloma cell lines compared with bortezomib. Carfilzomib 
also overcame both primary and secondary resistance to 
bortezomib in both cell lines and patient-derived clinical 
samples. This observation was made in dexamethasone-
resistant and melphalan-resistant cell lines, although the 
doxorubicin-resistant cell line did not respond to carfil-
zomib unless the cell line was pretreated with verapamil, 
a P glycoprotein inhibitor. In order to mimic the in vivo 
pharmacokinetic profile of proteasome inhibitor treatment, 
RPMI 8226 cells were treated with a one-hour pulse of 
drug followed by a washout. Accumulation of ubiquitin 
bound proteins and proapoptotic Bax, a proteasome target, 
were observed up to 48 hours after treatment, suggesting 
durable proteasome inhibition by carfilzomib. Inhibition of 
cell proliferation resulted in apoptosis which was associated 
with activation of c-Jun-N-terminal kinase, mitochondrial 
membrane depolarization, release of cytochrome c, and acti-
vation of both intrinsic and extrinsic caspase pathways. Both 
continuous and pulse administration of carfilzomib inhibited 
proliferation and induced programmed cell death in patient-
derived multiple myeloma cells and neoplastic cells.
In another recent study, Suzuki et al demonstrated that a 
bortezomib-resistant human colorectal adenocarcinoma cell 
line (HT-29) demonstrated high basal levels of proteasome 
catalytic activity (7–11-fold) compared with a bortezomib-
sensitive cell line.30 Four hours after exposure to bortezomib, 
the resistant cells exhibited rapid recovery of proteasome 
activity relative to the sensitive cells, although carfilzomib 
induced prolonged inhibition of the proteasome in both 
bortezomib-sensitive and bortezomib-resistant cells, pro-
viding a possible explanation of its clinical activity in both 
bortezomib-naïve and bortezomib-treated patients. Resistant 
cells did not recover their proteasome activity to levels seen in 
parental cells at 24 hours after a brief exposure to bortezomib. 
This suggested alterations in proteasome assembly as a pos-
sible mechanism for the resistance to bortezomib. Sequence 
analysis of these resistant cells demonstrated a mutation in 
the propeptide region of the β5 subunit of the proteasome 
(Arg24Cys). This region is required for proper proteasome 
assembly, and has previously been identified at a high fre-
quency in myeloma patients.31 Suzuki et al30 also identified a 
novel mutation in LMP7 that might be responsible for rapid 
and efficient recovery of the proteasome and may explain the 
clinical resistance to bortezomib seen in myeloma patients. 
Carfilzomib was able to overcome bortezomib resistance in 
these cells due to prolonged irreversible inhibition of the 
proteasome. Collectively, these in vitro data highlight the Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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potential of carfilzomib to overcome proliferation and induce 
apoptosis in both bortezomib-naïve and bortezomib-treated 
multiple myeloma cells without enhanced toxicity.
In order to evaluate if the myeloma cells in the bone 
marrow were equally vulnerable to proteasome inhibition 
by carfilzomib compared with peripheral blood mononuclear 
cells, Trudel et al measured the proteasome activity in both 
populations of cells.32 They employed an enzymatic assay 
using a fluorogenic substrate for the chymotrypsin-like activ-
ity and an enzyme-linked immunosorbent assay to quantitate 
inhibition of chymotrypsin-like and 20Si subunits (LMP7 
and MECL1). Their results demonstrated that carfilzomib 
inhibited proteasome activity in myeloma cells in the bone 
marrow to the same extent as that seen in the mononuclear 
cells in whole blood. These data established that evaluating 
the peripheral blood mononuclear cells is a reasonable sur-
rogate marker for proteasome inhibition in tumors, at least 
for multiple myeloma involving the bone marrow.
in vitro activity in acute myelogenous 
leukemia
Stapnes et al demonstrated that carfilzomib, like bortezomib, 
inhibited autocrine-dependent and cytokine-dependent 
proliferation of primary acute myelogenous leukemia blasts 
when tested at nanomolar concentrations (0.1–100 nmol/L).33 
Carfilzomib enhanced apoptosis in acute myelogenous 
leukemia cells and decreased proliferation and viability of 
tumor cells when tested in combination with idarubicin and 
cytarabine. Antiproliferative effects were also seen in human 
acute lymphoblastic leukemia cells. These data demonstrate 
the wide spectrum of antitumor activities exhibited by carfil-
zomib across various hematologic malignancies other than 
multiple myeloma.
in vitro activity in non-Hodgkin’s 
lymphoma in combination with histone 
deacetylase inhibitors
Dasmahapatra et al demonstrated that the activity of carfil-
zomib in both germinal-center B cell-like diffuse large B 
cell lymphoma and activated B cell-like diffuse large B cell 
lymphoma was enhanced with coadministration of vorinos-
tat, a histone deacetylase inhibitor.34 Vorinostat increased the 
carfilzomib activity in diffuse large B cell lymphoma cells 
resistant or sensitive to bortezomib. This was mediated via 
increased mitochondrial injury, caspase activation, apoptosis 
through Jun NH2-terminal kinase and p38 mitogen-associ-
ated protein kinase activation.   Abrogation of histone deacety-
lase inhibitor-mediated nuclear factor-kappa B activation, 
AKT inactivation, and Ku70 acetylation, was also observed, 
which contributed to the synergistic activity. To date, this 
synergy has not been explored in preclinical models of 
multiple myeloma but supports investigation. Recently Rao 
et al reported that when mantle cell lymphoma cells were 
cotreated with a specific histone deacytelase-6 inhibitor, WT 
161, it disrupted hsp-90 function, abrogated aggresome for-
mation, and sensitized the cells to lethal endoplasmic reticu-
lum stress induced by carfilzomib.35 As already established 
with bortezomib, these observations highlight the potential 
of combining carfilzomib with other chemotherapeutics, 
especially histone deacetylase inhibitors.
in vivo activity
Demo et al demonstrated that carfilzomib was able to induce 
apoptosis in human tumor xenograft models of colorectal 
cancer, B cell lymphoma, and Burkitt’s lymphoma, with daily 
dosing schedules that also induced high levels of proteasome 
inhibition.14 Importantly, Demo et al established that dosing 
for two consecutive days exhibited superior antitumor activ-
ity in xenograft tumors when compared with carfilzomib or 
bortezomib given in a split dosing schedule (day 1 and day 
4) or on a higher-dose weekly schedule, suggesting that the 
improved efficacy with a consecutive day schedule could 
be due to inhibition of proteasome recovery between doses. 
Despite this intensive daily dosing that resulted in greater 
than 80% proteasome inhibition in most tissues, it was well 
tolerated without any excessive toxicity. These data led to 
the selection of the two consecutive day schedules for Phase I 
clinical trials.
Pharmacokinetic and 
pharmacodynamic profile
Studies in rodents and nonhuman primates have demon-
strated that carfilzomib is rapidly cleared from the plasma 
compartment following intravenous bolus administration, 
with a terminal half-life in rats and monkeys of 15 and 
7.2 minutes, respectively.36 Despite the rapid clearance, 
carfilzomib produced a prolonged dose-dependent inhibition 
of 20S proteasome in all tissues except the brain. In rats and 
monkeys, carfilzomib was administered for either two or five 
consecutive days, followed by nine days of rest for two 14-day 
cycles. Doses that resulted in greater than 80% inhibition of 
proteasome activity in blood and other tissues were found 
to be well tolerated.14 It was also superior to the split dosing 
schedule (day 1 and day 4). Recovery of proteasome activity 
following repeated daily administrations was unchanged from 
that seen after a single dose. A transient thrombocytopenia Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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was noted in both rats and monkeys following administra-
tion of carfilzomib, but neutrophil and lymphocyte counts 
remained unchanged. These observations established the 
rationale for the schedule-dependency and likely antitumor 
activity, and formed the basis for the design of the first Phase 
I dose escalation study.37 In this first Phase I experience by 
O’Connor et al, 29 patients with refractory or relapsed mul-
tiple myeloma, non-Hodgkin’s lymphoma, Waldenstrom’s 
macroglobulinemia, or Hodgkin’s lymphoma were enrolled. 
Patients received carfilzomib every day for five consecutive 
days every 14 days at doses of 1.2, 2.4, 4.6, 8.4, 11, 15, and 
20 mg/m2. No dose-limiting toxicities were observed in 
the 1.2–15 mg/m2 cohorts. However, at the 20 mg/m2 dose, 
grade 3 febrile neutropenia, and grade 4 thrombocytopenia 
(two patients of five in that cohort) were noted, establishing 
15 mg/m2 as the maximum tolerated dose. Antitumor   activity 
was observed at doses greater than 11 mg/m2, including 
one unconfirmed complete response (mantle cell lym-
phoma), one partial response (multiple myeloma), and two 
minimal responses (multiple myeloma and   Waldenstrom’s 
  macroglobulinemia). The mean maximum concentration 
for the 15 mg/m2 dose was 325.9 (83.7–620) ng/mL, time to 
maximum concentration was 5.8 (5–7) minutes, area under 
the curve was 9728 (1616–28,426) ng-mL/hour, elimination 
half-life was 28.9 (6.8–95.5)   minutes, systemic clearance 
was 7054 (950–18,511) mL/min and volume of distribu-
tion at steady state was 942 (1417–4603) L. Clearance was 
rapid, with an elimination half-life of less than 30 minutes, 
in accordance with preclinical data and through renal and 
biliary excretion. Although the peak concentration and area 
under the curve increased with dose, the increase was not 
dose-proportional. Mild to moderate fatigue (48%, n = 14), 
nausea (48%, n = 14), diarrhea (35%, n = 10), dyspnea 
(28%, n = 8), pyrexia (28%, n = 8), hypoesthesia (28%, 
n = 8), headache (24%, n = 7), constipation (21%, n = 6), 
peripheral edema (24%, n = 7), and anemia were reported. 
Forty-eight percent (n = 14) of the patients experienced grade 
3–4 toxicity, but no patient experienced grade 3–4 peripheral 
neuropathy, despite inclusion of patients with symptomatic 
or pre-existing neuropathy. These data were among the first 
to establish the reduced incidence of neuropathy associated 
with carfilzomib.
Pharmacodynamic studies in this trial showed that 
carfilzomib induced a dose-dependent inhibition of 20S 
chymotrypsin-like proteasome activity in whole blood and 
peripheral blood mononuclear cells within one hour of 
drug administration on day 1. More than 75% inhibition 
of chymotrypsin-like activity was achieved in whole blood 
and peripheral blood mononuclear cells with the first dose 
of carfilzomib $ 11 mg/m2. With repeat dosing, cumulative 
proteasome inhibition was observed in whole blood and 
peripheral blood mononuclear cells within one hour after the 
fifth consecutive day of dosing in the highest dose groups, 
which was also well tolerated. Activity generally returned 
to the baseline in peripheral blood mononuclear cells dur-
ing the nine-day rest period, but only partially recovered in 
whole blood due to the inability of erythrocytes to synthesize 
new proteasome protein. No unexpected adverse events 
were associated with the extended five-day dosing with 
  carfilzomib. This study demonstrated activity of carfilzomib 
in multiple hematologic malignancies, including bortezomib-
resistant multiple myeloma, confirmed sustained inhibition 
of the chymotrypsin-like activity of the proteasome subunit, 
and established the drug and the schedule as safe.
In order to evaluate the efficacy, safety, and pharmacoki-
netic and pharmacodynamic profile of an intravenous bolus 
versus a protracted infusion (over 30 minutes) schedule of 
carfilzomib, a Phase Ib/II study (PX-171-007) was conducted 
by Rosen et al in patients with advanced metastatic solid 
tumors.38,39 The Phase I bolus trial enrolled patients with 
solid tumors failing at least two prior treatments. Carfilzomib 
was given on days 1, 2, 8, 9, 15, and 16 every 28 days for up 
to 12 cycles. During cycle 1, day 1 and day 2 dosing in all 
cohorts was 20 mg/m2, with subsequent escalation to 20, 27, 
or 36 mg/m2 on day 8. One patient who received the 36 mg/m2 
dose on day 8 developed a dose-limiting toxicity (grade 3 
fatigue). Hence 20 mg/m2 was selected as the Phase II dose. 
Fourteen patients were enrolled in the Phase I bolus trial, 
20 patients in the Phase I infusion study and 65 patients in the 
Phase II study, which included 12 small cell lung cancers, 17 
non-small cell lung cancers, 16 ovarian, 10 renal, and 24 other 
cancers. A separate treatment arm was added for patients 
with multiple myeloma in this category. Partial responses 
were seen in patients with renal cancer, non-small cell lung 
cancer, and multiple myeloma, whereas stable disease last-
ing for greater than 16 weeks was observed in patients with 
mesothelioma, ovarian, renal, cervical, endometrial, small 
cell lung, and non-small cell lung cancer. As noted in the 
earlier Phase I studies, no patients experienced greater than 
grade 1 peripheral neuropathy, even at the highest doses of 
carfilzomib administered (ie, 36 mg/m2 on day 8). These 
data established that carfilzomib was tolerated and equally 
efficacious as a bolus and infusion administration.
A second parallel Phase1 trial (PX-171-002) conducted 
by Alsina et al evaluated a consecutive day schedule for three 
consecutive weeks on a 28-day cycle (days 1 and 2, days Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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8 and 9, days 15 and 16, every 28 days) at doses ranging 
from 1.2 mg/m2 to 27 mg/m2 in 37 patients with relapsed 
or refractory lymphoid neoplasms and multiple myeloma.40 
They found that 15 mg/m2 was the minimum effective dose, 
with greater than 80% proteasome inhibition being achieved 
at this dose, with good tolerability. Five objective responses 
were observed in 16 patients (13 multiple myeloma, three 
mantle cell lymphoma) enrolled at the minimum effective 
dose or higher. Four patients with multiple myeloma attained 
a partial response, and one patient with multiple myeloma 
attained a minimal response. The responses were durable 
(134–392 days), and occurred in patients who relapsed fol-
lowing prior bortezomib, immunomodulatory agents like 
thalidomide and lenalidomide, and stem cell transplantation. 
A reversible grade 2 first-dose effect of increased creatinine 
at doses of 20 mg/m2 and higher was observed. Given the 
safety and efficacy of this schedule, it was chosen as the 
Phase II dose for patients with multiple myeloma and other 
solid tumors in refractory/relapsed settings.
Clinical activity
Given the encouraging safety profile and clinical activity 
observed in the Phase I studies, Phase II trials of carfilzomib 
were initiated in patients with relapsed and refractory multiple 
myeloma. In an open-label, multicenter trial,   Jagannath et al 
demonstrated dramatic single agent activity of carfilzomib 
in patients with relapsed and refractory multiple myeloma.41 
Forty-six patients with multiple myeloma, who had relapsed 
disease following at least two prior therapies, received carfil-
zomib at a dose of 20 mg/m2 intravenously on days 1, 2, 8, 9, 
15, and 16 every 28 days for up to 12 cycles. The median num-
ber of prior therapies was five (range 2–15), which included 
an anthracycline and alkylating agent, and 83% had had a 
prior stem cell transplant. Patients received a median of three 
cycles of carfilzomib (range 1–12).   Clinical response, defined 
as minimal response or greater, was seen in 10 patients (26%), 
including five patients achieving a partial response and five 
patients attaining a minimal response. No patients achieved a 
complete remission. Five patients with bortezomib-refractory 
disease achieved a minimal response or a partial response. 
The median time to progression was 6.2 months, while the 
median duration of response was 7.4 months. This time to 
progression is similar to that observed with bortezomib in 
both the SUMMIT trial conducted in relapsed and refractory 
multiple myeloma patients (median time to progression seven 
months) and the APEX trial conducted in patients who had 
relapsed myeloma (median time to progression 6.2 months). 
Ten percent of the patients (four of 39) completed 12 cycles, 
highlighting that prolonged treatment with carfilzomib is 
possible. Eight of the 10 patients achieved a response during 
cycle 1, and peripheral neuropathy was noted in less than 
10% of the patients, with one grade 3 neuropathy occurring 
in a patient with pre-existing grade 2 neuropathy. Common 
adverse events included fatigue (65%), anemia (65%), throm-
bocytopenia (46%), neutropenia (20%), nausea (37%), upper 
respiratory infection (37%), and diarrhea (33%). Increased 
creatinine, both drug and nondrug-related, was seen in 15 of 
46 patients (33%), but treatment was discontinued in only 
three patients due to nephrotoxicity. Acute renal failure was 
documented in four patients (9%), two (4%) of whom also 
had possible tumor lysis syndrome, thus making it difficult to 
discern completely the effect of carfilzomib on renal   function. 
This was the first Phase II clinical study of carfilzomib, which 
showed single-agent activity in a heavily pretreated, relatively 
bortezomib-resistant population of patients with relapsed or 
refractory multiple myeloma.
These encouraging results led to PX-171-003-A1, 
an open-label, Phase IIb trial conducted by the Multiple 
Myeloma Research Consortium.42 Two hundred and sixty-six 
patients with refractory multiple myeloma were included. 
Patients were required to have had at least two prior thera-
pies, including bortezomib and either thalidomide or lenali-
domide, and an alkylating agent. The enrolled patients had 
received a median of five prior lines of therapy (range 1–20 
and a median of 13 antimyeloma agents). Of note, the major-
ity of the patients had failed at least two prior bortezomib-
  containing regimens. Patients received carfilzomib at 
20 mg/m2 on days 1, 2, 8, 9, 15, and 16 every 28 days in cycle 
1, and were dose-escalated to 27 mg/m2 on the same schedule 
thereafter for up to 12 cycles. The primary endpoint was 
overall response rate. An overall response rate of 24% with a 
median duration of response of 7.4 months (range 6.2–10.3) 
was observed. One complete response (0.4%), 12 very good 
partial responses (4.7%), 48 partial responses (19%), and 
32 minimal responses (12%) were achieved. An additional 
eighty three (32%) patients achieved stable disease for at 
least six weeks. Eleven percent of the patients completed the 
entire 12 cycles and went on into the extension study. The 
most common treatment-emergent adverse events $ grade 
3 regardless of the relationship to study drug were hemato-
logic, including thrombocytopenia (22%), anemia (20%), 
lymphopenia (10%), pneumonia (8%), neutropenia (8%), 
fatigue (7%), hyponatremia (5%), and hypercalcemia 
(5%). Although 206 (77%) patients experienced grade 1 or 
2 peripheral neuropathy at baseline, new onset peripheral 
neuropathy was infrequent. Greater than grade 3 neuropathy Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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occurred in less than 1% of patients. Analysis of this subset 
of patients with active peripheral neuropathy (grade 1 and 2) 
in this trial demonstrated that peripheral neuropathy had no 
impact on the depth or durability of responses, or on the 
tolerability of carfilzomib. This Phase II study demonstrated 
that single-agent carfilzomib can induce durable responses 
in heavily pretreated multiple myeloma patients who had 
failed multiple chemotherapy regimens, including those 
containing bortezomib and immunomodulatory agents. 
  Significantly, even patients with baseline neuropathy toler-
ated prolonged treatment with carfilzomib, with minimal 
risk of exacerbation.
A second parallel Phase II multicenter study (PX-171-004) 
of carfilzomib was conducted by the Multiple Myeloma 
Research Consortium to determine its efficacy in bortezomib-
naive relapsed multiple myeloma patients.43–46 Fifty-four 
patients received carfilzomib at a dose of 20 mg/m2 intrave-
nously on days 1, 2, 8, 9, 15, and 16 every 28 days for up to 
12 cycles, while 19 patients received the escalated dose of 
27 mg/m2 on the same schedule. The overall response rate was 
46% (25 of 54 patients), which included one overall response 
rate, five very good partial responses, and 19 partial responses 
at the 20 mg/m2 dose. In addition, nine patients experienced 
a minimal response and 10 patients had stable disease. At 
the 27 mg/m2 dose, the overall response rate was 53%, with 
one very good partial response and nine partial responses. 
The median duration of response was 8.8 months and the 
median time to progression was 7.6 months. The adverse 
events were similar to the previous studies, and included 
fatigue (59%), nausea (41%), dyspnea (36%), anemia 
Table 2 Comparison of the early-phase trials of major proteasome inhibitors in clinical use
Outcome Bortezomib Carfilzomib NPI-0052
Maximum tolerated dose/schedule 1.3 mg/m2 on days 1, 4, 8, and 
11 every 21 days
20 mg/m2 on days 1, 2, 8, 9, 
15, and 16 every 28 days
0.7 mg/m2 on days 1, 8, 
and 15 every 28 days
Dose-limiting toxicity Thrombocytopenia, 
hyponatremia, fatigue
Fatigue Fatigue, mental status 
change, loss of balance
Phase ii, Richardson et al4 ii, Jagannath et al41 i, Richardson et al78
ORR n (%) 67 (35) 61 (24) 1 (3.5)
n 193 266 27
CR or nCR 
Patients (n, %)
19 (10) 1 (0.4) None
PR 
Patients (n, %)
34 (18) 48 (19) 1 (3.5)
Median duration of response 12 months 7.4 months Not reported
Median TTR 1.3 months 1 month Not reported
Median TTP 7 months Not reported Not reported
Grade 3 peripheral neuropathy (%) 12% ,1% None
Developmental stage Approved for MM and relapsed MM Phase ii Phase i
Abbreviations: ORR, overall response rate, ie, $ PR; CR, complete remission; nCR, near complete remission; n, number of patients enrolled in the trial; PR, partial 
response; DoR, duration of response; TTP, time to progression; TTR, time to a first response; MM, multiple myeloma.
(29%), increased creatinine (31%), and upper respiratory 
tract infection (31%), with most # grade 2. Grade 3 and 4 
adverse events which occurred in 5% or more patients were 
thrombocytopenia (9%), fatigue (9%), neutropenia (7%), 
lymphopenia (7%), anemia (5%), pneumonia (5%), and 
hyperglycemia (5%). Dose reductions were rarely invoked, 
and the drug was well tolerated in patients with baseline 
renal insufficiency. Increased creatinine, irrespective of attri-
bution, was seen in five patients (16%), but treatment was 
discontinued in only one patient due to a renal adverse event. 
Subsequently, patients in this study were stratified into a high-
risk category based on their Eastern Cooperative Oncology 
Group performance score, cytogenetic profile, and serum β2 
microglobulin, and responses of this subset were analyzed. 
Single-agent carfilzomib produced an overall response rate of 
41%–54% in this high-risk group, highlighting its potential as 
a steroid-sparing agent in patients with multiple comorbidi-
ties. Comparison of the early-phase results of some of the 
proteasome inhibitors currently in clinical use in multiple 
myeloma are summarized in Table 2.
Jakubowiak et al recently evaluated the influence of   disease 
cytogenetics in 79 patients enrolled in the PX-171-003 and 
PX-171-004 trials, in whom metaphase cytogenetics and/or 
fluorescence in situ hybridization analysis for del 13q, t(4;14) 
and t(14;16) chromosomal abnormalities were   available.47 The 
response rate ($minimal response) for the entire group of 
patients was 40.5%. Twenty-three of the 79 patients had at least 
one of the cytogenetic abnormalities. However, the   presence 
of these cytogenetic lesions did not impact the response rate. 
Approximately 43% of patients with one or more genetic Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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lesions responded, compared with 39.3% of patients with no 
cytogenetic abnormality. The median time to progression was 
203 days for all patients in this analysis, with a time to progres-
sion of 195 days for patients with one or more abnormalities, 
and 208 days for patients with none. Similar to what has 
been seen with bortezomib, these data appear to suggest that 
carfilzomib has efficacy even in patients with well established 
adverse prognostic factors in myeloma.
Given the preclinical evidence of synergy between carfil-
zomib and dexamethasone demonstrated by Kuhn et al,29 a 
Phase Ib study of carfilzomib (PX-171-006) in combination 
with lenalidomide and low-dose dexamethasone was con-
ducted by Niesvizky et al in patients with relapsed and refrac-
tory multiple myeloma.48,49 The aim was to assess the safety 
and feasibility of this combination. Sixty-seven patients with 
a median of two prior therapies (including lenalidomide, 
thalidomide, bortezomib, stem cell transplant, alkylators, 
and anthracyclines) were enrolled. Carfilzomib was admin-
istered in doses ranging from 15 mg/m2 to 27 mg/m2 on 
days 1, 2, 8, 9, 15, and 16 intravenously), lenalidomide in 
doses ranging from 10 mg to 20 mg orally on days 1 and 2, 
and low-dose dexamethasone at a dose of 40 mg orally on 
days 1, 8, 15, and 22 in 28-day cycles. The regimen induced 
rapid responses within the first cycle in most patients. The 
overall response rate and clinical benefit response (defined 
as minimal response or better) for 29 evaluable patients was 
59% and 72%, respectively, which included a 21% overall 
response rate/near overall response rate (n = 6), a 17% very 
good partial response rate (n = 5), and a 21% partial response 
rate (n = 6). Forty-three of the 67 patients had remained 
on the study at the time when the results were reported. 
Grade 3 hematologic toxicity was minimal and reversible, ie, 
thrombocytopenia (n = 6), anemia (n = 4), and neutropenia 
(n = 6). Other toxicities, including fatigue and neuropathy, 
did not exceed grade 2. Interestingly, the tolerability of the 
regimen allowed continued administration of the combina-
tion for up to 18 cycles, and prior exposure to bortezomib 
and immunomodulatory drugs did not preclude the patients 
from achieving a response.
Alsayed et al conducted a small trial exploring the 
coadministration of carfilzomib with other agents, such as 
dexamethasone, liposomal doxorubicin, thalidomide, cispla-
tin, and vorinostat, in a graded manner in 17 patients with 
advanced, refractory multiple myeloma and high-risk gene 
expression profiles.50 Seventeen heavily pretreated patients 
received carfilzomib 20 mg/m2 on days 1 and 2, and 27 mg/m2 
on days 8, 9, 15, and 16, along with dexamethasone 4 mg 
with each dose of carfilzomib. Thirteen patients started the 
second cycle of carfilzomib at 36 mg/m2, along with dexam-
ethasone ranging in dose from 4 mg to 20 mg. Nine patients 
started the third cycle of carfilzomib at 36 mg/m2, along with 
dexamethasone, with the addition of thalidomide 100 mg/day 
and doxorubicin 3 mg/m2/day × 16 days for one cycle. Four 
patients received a fourth cycle as in cycle 3 with added cis-
platin at 2 mg/m2/day for 16 days for one cycle. Two patients 
finished a fifth cycle with further addition of vorinostat 
200 mg/day. Responses included one overall response (cycle 
1), three partial responses (two in cycle 2, one in cycle 4), 
and four improvements. Toxicities attributed to carfilzomib 
were minor, with no evidence of bone marrow or kidney 
dysfunction or peripheral neuropathy. This study provides a 
platform for the use of carfilzomib in combination with other 
approved drugs without any enhanced toxicity.
Given the incidence of renal impairment in patients 
with myeloma, an organ dysfunction study (PX-171-005) 
was performed by Bardos et al.51,52 Thirty-nine patients 
were enrolled into the study. Ten patients with normal renal 
function, nine with mild renal insufficiency (creatinine 
clearance 50–79 mL/min), nine with moderate (creatinine 
clearance 30–49 mL/min), nine with severe renal insuffi-
ciency   (creatinine clearance , 30 mL/min), and two patients 
on hemodialysis were included. These patients received 
carfilzomib at a dose of 15 mg/m2 in cycle 1, escalating to a 
20 mg/m2 schedule in cycle 2 and 27 mg/m2 in cycle 3. Renal 
impairment did not affect the pharmacokinetic or pharmaco-
dynamic profile across all categories of renal dysfunction. 
Carfilzomib was undetectable in plasma within three hours, 
and did not accumulate after cycle 2. Of note, eight partial 
responses, five minimal responses, and 13 patients with 
stable disease were observed despite renal impairment. This 
study clearly establishes the safety and similar efficacy of 
carfilzomib administration in patients with marked renal 
insufficiency, a well known feature in multiple myeloma, 
without dose adjustments.
Collectively, these trials establish the significant activity 
and favorable safety profile of carfilzomib in patients with 
heavily treated myeloma. Carfilzomib appears to distinguish 
itself from bortezomib mostly with regard to its favorable tox-
icity profile with substantially less neurotoxicity. The results 
of major clinical trials performed to date with carfilzomib 
are summarized in Table 3.
Side effect profile
One of the major complications and the dose-limiting toxicity 
of agents active in multiple myeloma like bortezomib and 
thalidomide, is debilitating peripheral neuropathy. While Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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the exact mechanism behind this toxicity remains poorly 
understood, it appears that this may not be a class effect of 
proteasome inhibitors.
Vij et al evaluated the neuropathic effects of carfilzomib 
in patients enrolled in the Phase II trials (PX-171-003 and 
PX-171-004).53 Detailed neurological examinations and 
subjective reporting of peripheral neuropathy using the FACT-
GOG/Ntx subscale version 4 questionnaire were recorded 
every two cycles until discontinuation of the drug. At the 
time the results were reported, data were available for 136 
patients. Seventy-three patients had peripheral neuropathy at 
baseline (64 with grade 1 and nine with grade 2) primarily 
attributed to prior use of thalidomide or bortezomib in the 
majority of cases. The median number of carfilzomib cycles 
received by the patients was 4.5. Peripheral neuropathy was 
reported in 21 (15%) patients, with 12 cases (9%) attributed 
to carfilzomib. The incidence of grade 3 or greater periph-
eral neuropathy was only 2% (n = 3), while the incidence 
of grade 1 or grade 2 paresthesias and dysesthesias was 
7% (in 10 patients only). None of the 136 patients required 
discontinuation or dose adjustments because of neurotox-
icity, and there was no statistically significant change in 
FACT-GOG/Ntx scores before and after starting carfilzomib. 
These data clearly establish the favorable side effect profile 
of carfilzomib, which does not appear to require major dose 
or schedule modifications even in patients with pre-existing 
neuropathy. The precise reason why carfilzomib exhibits less 
neurotoxicity compared with bortezomib is unclear, with 
many attributing the differences to its selectivity and lack of 
off-target effects. An in vitro neurotoxicity model established 
to compare treatment-induced peripheral neuropathy between 
carfilzomib and bortezomib demonstrated that, after treat-
ment with bortezomib, differentiated neuroblastoma cells 
showed a 40% reduction in neuron length compared with 
carfilzomib.52 HtrA2/Omi, a mitochondrial serine protease 
with a role in neuron survival, has been confirmed as a target 
of bortezomib but not carfilzomib. It is interesting that the 
amount of proteasomal inhibition appears unrelated to the 
neuropathic effects, confirming that this is not a class effect 
of the proteasome inhibitors.
Aside from neurotoxicity, constitutional symptoms, such 
as fatigue, are seen in the majority of patients (57%–66%) 
treated with carfilzomib, although the majority of these events 
are primarily less than grade 2, with grade 3 or 4 fatigue 
occurring in about 9% of patients. None of these toxicities 
were associated with discontinuation of the drug and were 
independent of renal status. Flu-like symptoms were seen in 
three of 17 patients enrolled in the study reported by Alsayed 
et al, but none were greater than grade 2. Additionally, no 
cardiotoxicity, in particular QTc interval prolongation, has 
been noted with carfilzomib.
Hematologic adverse events were also considered to be 
relatively minor. Most are grade 2 or less, and include anemia 
(29%–65%), thrombocytopenia (25%–46%), and febrile neu-
tropenia (20%–42%). The overwhelming majority of these 
events were reversible during periods off the drug. Grade 3 or 
4 hematologic toxicity was seen in approximately 9%–10% of 
the patients. Overall, the spectrum of hematologic toxicities 
is not unexpected, and well within the realm of what has been 
previously reported with other proteasome inhibitors.
Some acute noncumulative elevations in creatinine have 
been seen with the first dose of carfilzomib, but none were 
irreversible or severe enough to cause toxicity or discontinu-
ation of therapy. Two cases of what appeared to be tumor 
lysis syndrome were observed early in the PX-171-003-A0 
trial, although no additional cases have been seen since 
routine prophylaxis for tumor lysis was incorporated into 
subsequent trials.
Interestingly, there have been no reported cases of zoster 
reactivation with carfilzomib, which has been reported with 
bortezomib. It is unclear at this time whether this is due to the 
fact that more patients were initiated on prophylactic antiviral 
agents pre-emptively, or whether there is a biological basis 
for the observation. Nonetheless, the absence of zoster reacti-
vation with carfilzomib seen thus far is considered a favorable 
distinguishing feature of this drug over bortezomib.
Unanswered questions
While there are clear differences in the biologic effects of 
carfilzomib compared with the other proteasome inhibitors, 
such as irreversible proteasome inhibition, greater selective 
action against the chymotrypsin-like subunit of the protea-
some, and more activity against the immunoproteasome, the 
clinical implications of these differences is only now begin-
ning to be established. Extensive literature has been published 
documenting the many pleiotropic effects of bortezomib on 
the bone marrow microenvironment and on the biology of the 
myeloma cells directly. There is less information regarding 
the ability of carfilzomib to induce similar effects in these 
model systems of myeloma.
As already mentioned, it is likely that nonselective 
proteasome inhibition by bortezomib may contribute to the 
induction of treatment-emergent neuropathy, which can be 
dose-limiting.55 While both bortezomib and carfilzomib 
appear to target the 20Si, along with the constitutively active 
proteasome, it remains to be determined whether carfilzomib Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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causes greater selective inhibition of the 20Si subunits, 
leading to decreased peripheral neuropathy, along with its 
ability to overcome bortezomib resistance. Fluorogenic 
enzyme assays to measure quantitative inhibition of the 20Si 
subunits are now available, and their incorporation in clinical 
trials might answer this question.
Differences in the pharmacology, potency, and efficacy 
across the proteasome inhibitors are incompletely understood. 
Bortezomib is a small boronic acid dipeptide molecule that 
mainly inhibits the chymotrypsin-like activity of the 20S 
proteasome. Relative to bortezomib, carfilzomib inhibits 
the chymotrypsin-like activity of the proteasome more 
selectively, with less cross-reactivity at the caspase-like 
and trypsin-like sites. Whether such selective proteasomal 
inhibition in the context of multiple myeloma makes it 
more potent and less toxic than NPI-0052, which appears 
to target all three catalytic sites, remains unknown. The 
comparative IC50 values of the above three agents for the 
different catalytic sites of the proteasome are listed in Table 1, 
and highlight the preferential activity of carfilzomib for the 
chymotrypsin subunit of the proteasome compared with bort-
ezomib and NPI-0052. It is also possible that the spectrum of 
proteasome inhibition might dictate the nature of the toxicity 
profile in patients treated with these   compounds. It would be 
interesting to see if this observation could be exploited to 
tailor individual therapy in patients with multiple myeloma 
and other hematologic malignancies without compromising 
efficacy. Additionally, the timing and method of carfilzomib 
incorporation in the treatment of patients with multiple 
myeloma will need to be addressed.
There have been several prospective Phase II trials of 
bortezomib in patients with relapsed or refractory mantle 
cell lymphoma, demonstrating overall response rates of 
29%–50% and complete response rates of 4%–8%.56–61 The 
median duration of response is approximately 10 months. 
Adverse events are similar to those previously reported for 
bortezomib in patients with multiple myeloma. This led to 
the approval of bortezomib for the treatment of patients with 
mantle cell lymphoma who have received at least one prior 
therapy. Obviously, one of the key questions that will need to 
be answered is whether similar response rates can be achieved 
with carfilzomib in non-Hodgkin’s lymphomas, such as 
mantle cell lymphoma. Of the five patients with mantle cell 
lymphoma treated with carfilzomib in the PX-171-001 trial, 
one patient achieved an unconfirmed overall response. Only 
one patient with Waldenstrom’s macroglobulinemia was 
included, who showed a 25% reduction in serum M protein 
after two cycles of carfilzomib at a dose of 15 mg/m2. In the 
PX-171-002 trial, of three patients with mantle cell lym-
phoma, two achieved stable disease with carfilzomib. While 
there definitely seems to be evidence of activity of carfilzomib 
in mantle cell lymphoma, the numbers of patients with this 
disease entity included in the trials of carfilzomib so far are 
too small to draw major conclusions at this juncture and need 
further investigation.
Combinations of bortezomib with other proven agents 
in relapsed and refractory multiple myeloma have shown 
promising results. Clinical trials of bortezomib in doublet 
drug combination regimens (bortezomib + melphalan 
or bortezomib + dexamethasone) have exhibited overall 
response rates of 63%–70% with complete response rates 
of 15%–23%.62–64 Trials with bortezomib in triplet drug 
combinations (bortezomib + cyclophosphamide + steroids, 
bortezomib + adriamycin + steroids, or bortezomib + lenali-
domide + steroids) have induced overall response rates of 
51%–82%, and overall response rates of 15%–27%.65–71 
Finally, combinations of bortezomib with three other agents 
active in multiple myeloma have demonstrated overall 
response rates of 67%–92% and complete response rates 
of 44%–53%.72–75 A Phase I trial by Niesvizky et al showed 
that carfilzomib can be safely combined with lenalidomide 
and dexamethasone, and induces a high overall response 
rate (59%–72%) and complete response rate (21%) without 
increased toxicity.48,49 Whether such synergy can be obtained 
with other chemotherapeutic agents and would be as effective, 
if not less, compared with bortezomib-based regimens, 
remains to be determined.
Given the plethora of proteasome inhibitors now being 
studied in the clinic, clearly it would be of value to be able 
to define those clinical scenarios where a particular protea-
some inhibitor will work. It remains unclear if the activity 
of these compounds will be limited to myeloma and selected 
forms of lymphoma, or whether differences in the underly-
ing molecular pharmacology will open new opportunities in 
other conditions.
Recently, Zangari et al reported that alkaline phosphatase 
variation during carfilzomib treatment is associated with the 
best response in multiple myeloma.76 They performed a 
retrospective analysis of serum alkaline phosphatase on 77 
patients enrolled in the PX-171-003 and PX-171-004 tri-
als. Increase in alkaline phosphatase from baseline, which 
was most evident during the second cycle of treatment, 
was significantly different in patients who achieved equal 
or greater than a very good partial response compared 
with all others on days 1 and 8 of cycle 2. In all patients 
achieving a very good partial response or better, alkaline Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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phosphatase increased by more than 15 U/L at cycle 2 on 
day 1 over the baseline. None of the patients with progres-
sive disease exhibited a similar increase, suggesting that 
this common blood test could be used as a surrogate to 
predict response.
Conclusion
It has been approximately 15 years since Julian Adams and his 
colleagues reported on the original synthesis and activity of 
bortezomib in in vitro and in vivo models of human cancer. In 
the past 15 years, our understanding of the ubiquitin-protea-
some pathway has become increasingly more sophisticated, 
now leading to the development of highly targeted drugs 
capable of targeting discrete ubiquitin E3 ligases.77 While the 
pace of our knowledge in this field continues to grow, there 
remains many important questions regarding the optimal 
strategies for use of these agents in the treatment of cancer. 
For example, is it better to develop more highly selective pro-
teasome inhibitors for one protease over another, or is it better 
to inhibit some combination of proteases   simultaneously? 
From a pharmacodynamic   perspective, is peak concentration 
or area under the curve of exposure the important determinant 
in exploiting the clinical activity of these compounds in the 
clinical setting? Nevertheless, despite multiple unresolved 
questions with respect to the role of carfilzomib in multiple 
myeloma and the fact that this is a targeted therapy with 
a pleiotropic effect, the data to date support the conten-
tion that carfilzomib has demonstrated significant clinical 
activity in patients with relapsed and refractory multiple 
myeloma, with good durability and tolerable side effects 
across all stages, irrespective of cytogenetic abnormalities 
and various degrees of renal   impairment. Its marked safety 
and comparable efficacy in multiple myeloma patients with 
pre-existing peripheral neuropathy makes it a drug that will 
integrate well with other active agents. Its efficacy in patients 
who have become refractory to other proteasome inhibitors, 
such as bortezomib, gives it a potentially significant role in 
clinical practice. It is clear that combination drug regimens 
in multiple myeloma are associated with higher overall and 
complete response rates, and are capable of inducing rapid 
response when required. It is safe to assume that future trials 
of carfilzomib evaluating its role either as a single agent or in 
combination with other agents, such as immunomodulatory 
agents and cytotoxic chemotherapy in both frontline and 
relapsed settings, will emerge in the years to come.
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